EMD Millipore and PharmaCell Announces Collaboration
Friday, May 24, 2013
Collaboration to evaluate EMD Millipore’s Mobius® bioreactor platform for expansion of HepaRG® cells.

WIL Research Partners with Three S Japan
Friday, May 24, 2013
Partnership to expand full portfolio of global safety assessment services to the Japanese market.

Merck Provides Update on Phase III Clinical Program for Preladenant
Friday, May 24, 2013
Merck provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD).

Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA
Friday, May 24, 2013
European Medicines Agency accepts regulatory submission of Type II variation for ABRAXANE for the treatment of advanced pancreatic cancer.

Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Friday, May 24, 2013
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.

Prosonix Initiates Phase 2 Clinical Study with PSX1002 in COPD Patients
Thursday, May 23, 2013
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix’ particle engineering platform.

Promedior Presents Encouraging Results from Clinical Study of PRM-151
Thursday, May 23, 2013
ATS oral presentation of phase 1b data highlights potential for novel mechanism to treat fibrosis.

NanoViricides, Inc. Files Positive Quarterly Report
Thursday, May 23, 2013
Company reports a strong cash position sufficient for initial clinical trials of its first drug candidate.

<<	1 2 3 4 5 6 7	>>
Showing Results 1 - 10 of 2264